Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas.
Aeglea BioTherapeutics, Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”AGLE” api=”yf” style=”font-size: 15px”]
BioStartup's Score 0 / 50